drugset / Trial / NCT00550095

To Assess the Effects of Valsartan on Albuminuria/Proteinuria in Hypertensive Patients With Type 2 Diabetes Mellitus

NCT00550095

Phase 4 Completed 509 enrolled Novartis
NaSingle-groupOpen-labelTreatment

Summary

This study is designed to assess the efficacy of the different dosage forms of Valsartan\[80, 160, and 320 mg\] in reducing microalbuminuria/proteinuria in hypertensive patients with type 2 diabetes.

Timeline

Start
2007-06
Primary completion
2009-11
Completion
2009-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Valsartan Small molecule 80 mg
Subject Valsartan Small molecule 160 mg
Subject Valsartan Small molecule 320 mg

Indications